Search

everythinglearnresearchcommunity

for

Search:↓

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

Verteporfin might be a potential cure for hair loss and could heal scars, which may lead to natural-looking results when combined with hairline lowering surgery. One person suggests waiting to see if verteporfin actually works as claimed.

A 22-year-old is using 1mg finasteride daily for hair loss, noting some scalp thickening but still experiencing visible thinning. They are considering oral minoxidil due to concerns about topical application with cats at home, and others in the conversation share positive experiences with oral minoxidil, reporting no side effects and significant hair regrowth.

The user shared their hair regrowth journey using treatments like dutasteride, minoxidil, microneedling, tretinoin, Nizoral, silica, biotin, and hormone replacement therapy (HRT) with cyproterone and estradiol. They reported substantial hairline improvement and some crown thinning, with hopes for further progress.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

A user shared a 12-month update on their hair transplant, which involved 5700 DHI grafts and cost £4500 at Cosmedica. They also dyed their hair and beard, and users praised the impressive results, suggesting finasteride or dutasteride to prevent further hair loss.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

The conversation discusses the use of Verteporfin in hair loss treatment. It suggests that Verteporfin could potentially regenerate hair follicles instead of forming scars, providing an unlimited donor supply for hair transplants.

KX-826 is available on Amazon but not shipped to the Netherlands. The user seeks advice on obtaining it in Europe.

Combining microneedling with Low Level Laser Therapy (LLLT) for hair growth, with discussions on device legitimacy and effectiveness. Alternatives like PEMF and the use of oral and topical treatments such as dutasteride, minoxidil, and finasteride are also considered.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The conversation is about starting a Discord group for people using KX-826 as their only treatment for hair loss, excluding those who are not serious or use multiple treatments. Someone agrees with the idea but mentions "GP :3," which is unclear.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

A long-term finasteride user is considering switching to dutasteride due to hair loss progression. Users share experiences with switching, noting side effects and varying effectiveness, with some experiencing shedding and others maintaining their hairline.

PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.

The conversation is about a user sharing their positive experience with Scalp Micropigmentation (SMP) for hair loss, highlighting the natural look achieved by a specialized artist. The procedure cost $2600 and was done by Alex Corona in Panama City Beach, FL.

Dutasteride capsules were exposed to heat and humidity, causing them to soften, and the user considered replacing them with new ones from a local pharmacy. Suggestions included alternating between old and new capsules, storing them properly, and using them topically with Minoxidil, though the user decided to wait and see the effects of Dutasteride first.

A user shared their positive experience with a non-surgical hair replacement system, detailing the purchase and maintenance process, including using Walker Lace Front Support Tape and various adhesives. They found the system secure and undetectable, allowing them to engage in active pursuits without issues.

PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

Carpronium chloride 5% is a hair growth treatment in Japan, considered less effective than minoxidil or finasteride. Some users report moderate success with it, but its efficacy is not well-verified.

Automatic-Law-3612's progress with hair loss treatments, including topical finasteride, topical dutasteride, minoxidil and pyrilutamide. They have been using these products for two weeks and noticed baby hairs in their temples getting longer.

The user experienced significant hair regrowth after using 1.25mg finasteride for 7 months, with no side effects, and is considering whether to keep or remove a previous SMP (scalp micropigmentation). They avoided minoxidil due to dandruff and sensitive scalp concerns, and they use a specific dandruff shampoo once a week.

Dr. Bloxham reported that Verteporfin is regenerating hair follicles. It might be a potential cure for hair loss.

Low-level laser therapy (LLLT) stimulates hair growth but current devices are expensive. A proposed non-profit project aims to create affordable, 3D-printed LLLT devices and collect data on their effectiveness.